What Juno Pharma Canada Inc. does

Juno Pharma Canada Inc. is a privately held Canadian specialty pharmaceutical company headquartered in Montreal, Quebec, with a secondary office in Mississauga, Ontario. Formed on April 1, 2025, through the merger of Juno Pharmaceuticals Corp. and Omega Laboratories Limited, the company develops, manufactures, markets, and distributes injectable and non-injectable medications for the Canadian healthcare industry and selected international markets. Its product portfolio spans hospital injectables (Sugammadex, NOROMBY/NOROMBY HP, Glucose 50% IV, Aminophylline, Famotidine), ophthalmic retail products (Bimatoprost Ophthalmic Solution 0.01% w/v), antiseptic skin preparations (STANHEXIDINE 2%/4%, Baxedin® 2%/20%/Pre-Op), phlebology/sclerotherapy agents (Sclerodex, Tromboject), and allergy/immunotherapy treatments marketed through the Omega Allergies & Immunotherapy sub-brand.

The company's core technical platform is its Health Canada- and U.S. FDA-approved sterile injectable manufacturing facility in Montreal, supported by GMP approvals for the EU, U.K., and Australia through Mutual Recognition Agreements. Manufacturing capabilities include aseptic filling and terminal sterilization, batch sizes from 50 to 500L, fill volumes from 1mL to 100mL, and automated/semiautomated/manual visual inspection. Endorsements from the European Medicines Agency and Japan's PMDA extend its regulatory reach. In addition to proprietary product manufacturing, Juno Pharma Canada offers contract development and manufacturing (CDMO) services covering formulation, aseptic filling, terminal sterilization, contract packaging, and visual inspection, alongside international product registration and export services.

The business operates across three revenue streams: direct pharmaceutical product sales to hospitals, pharmacies, and healthcare providers; CDMO/contract manufacturing services for pharmaceutical partners; and international product registration and licensing for export markets. GTM is executed via enterprise field sales and direct business development outreach ([email protected]), supplemented by a Shopify-based e-commerce catalog and the dedicated omegaallergies.ca channel. The company also maintains medical information, pharmacovigilance, and customer service functions, reflecting the regulatory obligations inherent to its pharmaceutical manufacturer status.

Name

Juno Pharma Canada Inc.

Legal name

Juno Pharma Canada Inc.

Website

https://junopharma.com

Company type

Private

Founded year

2025

Operating status

Operating

Short description

Juno Pharma Canada Inc. is a Canadian specialty pharmaceutical company that develops, manufactures, and distributes sterile injectable, ophthalmic, antiseptic, phlebology, and allergy/immunotherapy products for hospitals, pharmacies, and healthcare providers, and offers CDMO services to pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Specialty pharmaceuticals
• Sterile injectable manufacturing
• CDMO services
• Hospital pharmaceuticals
• Pharmaceutical distribution

Headquarters

HQ city

Montreal

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary and generic injectable and non-injectable medications through direct sales and distribution channels to healthcare providers
2. CDMO/Contract Manufacturing Services: Contract manufacturing for sterile injectable medications, contract packaging, and pharmaceutical development services for partners
3. International Product Registration and Export: Export and international registration of commercial sterile injectable products to other markets

Go-to-market motion1 record

Distribution channels4 records

Marketing channels2 records

Core offering

Juno Pharma Canada Inc. is a Canadian specialty pharmaceutical company that manufactures, markets, and distributes a portfolio of sterile injectable and other specialty pharmaceutical products — including hospital injectables, antiseptics, phlebology products, allergy medications, and ophthalmic solutions — to hospitals, pharmacies, and healthcare providers in Canada and through licensed international partners. In parallel, the company offers CDMO (Contract Development and Manufacturing Organization) services to third-party pharmaceutical partners, leveraging its sterile injectable manufacturing platform.

Product overview

Juno Pharma Canada Inc. is a Canadian specialty pharmaceutical company formed by the merger of Juno Pharmaceuticals Corp. and Omega Laboratories Limited (April 1, 2025). The company focuses on development, production, marketing, and distribution of injectable and non-injectable medications. The product portfolio spans: (1) Retail/Consumer Products including Bimatoprost Ophthalmic Solution for eye conditions, Sugammadex Injection, and Omega Allergies & Immunotherapy treatments; (2) Hospital/Hospital Products including Glucose IV Infusion, Aminophylline Injection, Famotidine Injection, and NOROMBY for sterile injectable medications; (3) Antiseptic Products including STANHEXIDINE and Baxedin® brand antiseptic solutions with various chlorhexidine gluconate concentrations; (4) Phlebology Products including Sclerodex and Tromboject for sclerotherapy; and (5) Contract Development & Manufacturing (CDMO) services for sterile injectables. The company operates Health Canada and FDA-approved manufacturing facilities with GMP approvals for EU, Australia, and UK markets.

Differentiator

Problem solved

Functional benefit

Brands

• Omega Allergies & Immunotherapy: Division of Juno Pharma Canada focused on allergy products and immunotherapy.

Products and services

• Sterile Injectable Hospital Products
• Antiseptic Products Antiseptic pharmaceutical products distributed by Juno Pharma Canada Inc. to hospitals, pharmacies, and healthcare institutions for infection control and topical use.
• Phlebology Products Phlebology pharmaceutical products marketed by Juno Pharma Canada Inc. for the phlebology specialty, distributed to healthcare providers and pharmacies.
• Allergy Products (Omega Allergies) Allergy medications marketed under the Omega Allergies branding, distributed by Juno Pharma Canada Inc. to retail pharmacies and healthcare consumers for allergy relief.
• Ophthalmic Solutions Ophthalmic pharmaceutical solutions, including Bimatoprost-based eye care products, marketed by Juno Pharma Canada Inc. for the ophthalmic specialty and distributed through pharmacies and healthcare channels.
• CDMO Services Contract Development and Manufacturing Organization (CDMO) services provided by Juno Pharma Canada Inc. to pharmaceutical partners, leveraging the company's sterile injectable manufacturing capabilities for formulation, fill-finish, and related contract manufacturing needs.

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Patheon (Thermo Fisher Scientific): Patheon, now part of Thermo Fisher's CDMO business, is a leading contract development and manufacturing organization serving pharmaceutical and biotech clients. Comparable to Juno's CDMO services in sterile injectable fill-finish, formulation development, and contract packaging for global pharma partners.
• Apotex Inc. Apotex is Canada's largest generic pharmaceutical manufacturer, producing sterile injectable and non-injectable generics with domestic and international distribution. Directly comparable to Juno Pharma Canada given overlapping Canadian generic injectable manufacturing, regulatory scope, and hospital-channel focus.
• Fresenius Kabi: Fresenius Kabi is one of the largest global suppliers of sterile injectable pharmaceuticals, IV solutions, and clinical nutrition products. Comparable to Juno in sterile injectable manufacturing, hospital channel distribution, and multi-jurisdictional regulatory footprint including Health Canada and FDA approvals.
• Hikma Pharmaceuticals: Hikma is a leading generic sterile injectable manufacturer with a large CDMO business and multi-jurisdictional regulatory approvals. Directly comparable to Juno's sterile injectable focus, CDMO service offering, and product development for generic injectables across regulated markets.
• Amphastar Pharmaceuticals: Amphastar specializes in injectable and intranasal generic pharmaceuticals with in-house manufacturing capabilities and FDA-approved facilities. Comparable to Juno's focus on complex sterile injectable generics and proprietary sterile manufacturing capabilities targeting shortage-prone molecules.

Emerging players

• Gland Pharma: Gland Pharma is an India-based sterile injectable manufacturer with FDA, EMA, and other major regulatory approvals, focused on generic injectables for global markets. Comparable to Juno in multi-jurisdictional sterile injectable manufacturing capabilities and CDMO services targeting complex generics.
• Ache Laboratorios Farmaceuticos: Ache is a Brazilian specialty pharmaceutical company with growing sterile injectable and hospital product portfolios expanding into international markets. Comparable to Juno as an emerging player in sterile injectable specialty pharma targeting hospital channels and seeking international registration of complex generics.

Broad incumbents

• Baxter International: Baxter is a global incumbent in sterile injectable pharmaceuticals, IV solutions, and hospital products with FDA-approved manufacturing. Comparable to Juno as a broad incumbent player with overlapping hospital sterile injectable portfolio but operating at materially larger scale with a much wider product breadth.
• Teva Pharmaceutical Industries: Teva is one of the world's largest generic pharmaceutical companies with a substantial sterile injectable portfolio. Comparable to Juno as a broad incumbent in generic injectables but operating globally at significantly larger scale with broader therapeutic coverage and biosimilar offerings.
• Sandoz (Novartis): Sandoz is the global leader in generic pharmaceuticals, including sterile injectable generics, with extensive multi-jurisdictional regulatory coverage. Comparable to Juno as a broad incumbent generic injectables player but at vastly greater scale with vertically integrated API and finished dose manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juno Pharma Canada Inc.